Parallax Volatility Advisers
KRYS icon

Parallax Volatility Advisers’s Krystal Biotech KRYS Stock Holding History

Parallax Volatility Advisers’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5,780
Closed -$404K – 2969
2021
Q4 		$404K Buy
+5,780
New +$336K ﹤0.01% 1505

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Parallax Volatility Advisers's KRYS Position: Q1 2022 in Review

Parallax Volatility Advisers sold out of Krystal Biotech (KRYS) in Q1 2022, closing a stake of 5,780 shares — an estimated $404K sold.

Parallax Volatility Advisers first reported a position in KRYS in Q4 2021 and held it in 1 quarter. The position peaked at $404K in Q4 2021. 135 funds tracked by Wall St. Rank hold KRYS as of Q1 2022.

  • Parallax Volatility Advisers reported no remaining Krystal Biotech position as of Q1 2022 after selling out during the quarter.
  • Parallax Volatility Advisers sold 5,780 Krystal Biotech shares in Q1 2022, an estimated $404K.
  • Parallax Volatility Advisers first reported a position in Krystal Biotech in Q4 2021 and held it in 1 quarter.
  • Parallax Volatility Advisers's Krystal Biotech position peaked at $404K in Q4 2021.
  • 135 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2022.

Based on Parallax Volatility Advisers's 13F filing for Q1 2022, filed 16 May 2022.